To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer



Status:Terminated
Conditions:Lung Cancer, Cervical Cancer, Cervical Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Women's Studies, Anemia, Bladder Cancer
Therapuetic Areas:Hematology, Oncology, Reproductive
Healthy:No
Age Range:18 - Any
Updated:11/19/2017
Start Date:January 2011
End Date:April 2013

Use our guide to learn which trials are right for you!

An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens

The purpose of this study was to determine an effective and safe dose of ACE-011 for the
treatment of chemotherapy induced anemia (CIA) in participants with metastatic non-small cell
lung cancer who are being treated with first-line platinum based chemotherapy.

The ACE-011-NSCL-001 Phase 2a study was an open-label, randomized, dose-ranging study
designed to assess the efficacy, safety, tolerability, pharmacokinetic and quality of life of
sotatercept (ACE-011) for treatment of CIA in participants with advanced or metastatic solid
tumors treated with platinum-based chemotherapeutic regimens. Other objectives included the
effect of sotatercept treatment on bone metabolism, the evaluation of the expression of
Activin A and other proteins/biomarkers (including myostatin and follistatin) and the
assessment of renal function biomarkers. The study consisted of a Screening Period, a
Treatment Period of approximately 6 months (up to 4 doses of sotatercept at either 15 mg or
30 mg administered subcutaneously every 42 days) and a Post-treatment Follow-up Period or End
of Treatment (42 days after the last dose of sotatercept). The study was terminated early due
to a slower than expected rate of enrollment as a result of substantial changes in the
standard of care for cancer participants with anemia which resulted in challenges to timely
accrual and completion of the study. Therefore, 26 participants were randomized into the
study and the planned Part 2 of the study consisting of a double-blind, randomized,
placebo-controlled Phase 2b/3 study conducted at the optimal dose of sotatercept (ACE-011) in
up to 750 subjects with metastatic NSCLC was not performed. Due to the small sample size and
variability of the data, changes were made to modify the study endpoints and revise them to
be exploratory only.

Inclusion Criteria:

1. Men and women > 18 years of age

2. Part 1: Histologically confirmed (cytology or biopsy) solid tumor malignancy,
excluding those solid tumors treated with curative intent.

Part 2: Histologically confirmed non-small cell lung cancer

3. Documented metastatic disease

4. Measurable or non-measurable disease evaluable by Response Evaluation Criteria in
Solid Tumors (RECIST) Version 1.1

5. All of the following laboratory values:

- Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L), due to chemotherapy-induced
anemia

- Absolute neutrophil count ≥ 500/mm^3

- Platelet count ≥ 75,000/mm^3 (> 72 hours since prior platelet transfusion

- Adequate renal function

- creatinine clearance ≥ 40mL/min or ≥ 50 mL/min if cisplatin is concomitantly
administered and

- urine protein / creatinine ratio ≤ 1.0; or ≤ 2.0 if bevacizumab (Avastin®)
is concomitantly administered

- Hepatic function (bilirubin < 1.5 x upper limits of normal (ULN); AST and ALT <
3.0 x ULN and ≤ 5.0 ULN for subjects with liver metastases)

6. Subjects must have received:

- at least one cycle and up to 4 cycles (q3w schedule) of platinum-based
chemotherapy and be randomized prior to receiving Cycle 5 OR

- at least one cycle and up to 3 months (depending upon regimen) of platinum-based
chemotherapy

7. >28 days since previous treatment with ESA

8. >14 days since last red blood cell transfusions

9. Eastern Oncology Cooperative Group (ECOG) Performance status 0-2

10. For females of childbearing potential, highly effective method of birth control for at
least 28 days before starting study, during participation and at least 112 days
following last dose of ACE-011

11. Males must use latex condom or non-latex condom not made of (animal) membrane during
any sexual contact with female of childbearing potential

12. Life expectancy of >3 months

13. Willing to adhere to study visit schedule

14. Understand and voluntarily sign informed consent

Exclusion Criteria:

Part 2 only, history of prior regimen(s)of platinum-based chemotherapy for metastatic NSCLC
and/or history of adjuvant platinum-based chemotherapy with last dose received less than
six months prior to the start of current first-line platinum-based chemotherapy for
metastatic NSCLC.

1. National Cancer Institute Common Terminology for Adverse Events Grade >3 toxicity

2. Prior radiation to >20% of whole skeleton

3. Prior regimen(s) of platinum based chemotherapy for metastatic disease and/or history
of adjuvant platinum-based chemotherapy with the last dose received less than six
months prior to the start of current first-line platinum-based chemotherapy for
metastatic disease

4. Central nervous system metastases

5. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic, or
genitourinary disease unrelated to underlying malignancy

6. Classification of 3 or higher heart failure (as classified by New York Heart
Association)

7. History of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke, if
not stable on anticoagulants and/or one of these events occurring in past 6 months

8. Diagnosis of a myeloid malignancy or known history of myelodysplasia

9. Recent history (within 14 days of Day 1) of IV/oral antibiotics due to post septic
episode

10. Uncontrolled hypertension. Controlled hypertension is considered clinically stable,
and systolic blood pressure (SBP) must be < 150 mmHg and diastolic blood pressure
(DBP) must be < 100 mmHg.

11. Known human immunodeficiency virus (HIV)

12. Known active hepatitis B or C antibody

13. Iron deficiency

14. History of anemia as a result of inherited hemoglobinopathy

15. History of anemia due to autoimmune or hereditary hemolysis or gastrointestinal
bleeding

16. Received treatment with another investigational drug or device within 28 days prior to
Day 1, or if the half life of the previous product is known, within 5 times the half
life prior to dosing, whichever may be longer.

17. Any prior use of Sotatercept (ACE-011).

18. Pregnant or lactating females or females planning to become pregnant

19. History of severe allergic or anaphylactic reactions or hypersensitivity to
recombinant proteins or excipients in the investigational product (Refer to the
Investigator's Brochure for further information).

20. Major surgery within 30 days prior to Day 1 (subjects must have completely recovered
from any previous surgery prior to Day 1).
We found this trial at
41
sites
Grand Junction, Colorado 81501
?
mi
from
Grand Junction, CO
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Anaheim, California 92801
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Bakersfield, California 93309
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Bedford, Texas 76022
?
mi
from
Bedford, TX
Click here to add this to my saved trials
Bend, Oregon 97701
?
mi
from
Bend, OR
Click here to add this to my saved trials
801 North 29th Street
Billings, Montana 59107
406-238-2500
Billings Clinic Based in Billings, Montana, Billings Clinic is a community-governed health care organization consisting...
?
mi
from
Billings, MT
Click here to add this to my saved trials
41 Mall Road
Burlington, Massachusetts 1805
781-744-5100
Lahey Clinic When Frank Lahey, MD, founded a group practice in 1923, his vision was...
?
mi
from
Burlington, MA
Click here to add this to my saved trials
4875 Higbee Ave NW
Canton, Ohio 44718
330-492-3345
Gabrail Cancer Center Since 1990, Gabrail Cancer Center has built a national reputation for excellence...
?
mi
from
Canton, OH
Click here to add this to my saved trials
Cedar Rapids, Iowa 52402
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Fountain Valley, California 92708
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Fullerton, California 92835
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
?
mi
from
Henderson, NV
Click here to add this to my saved trials
?
mi
from
Joliet, IL
Click here to add this to my saved trials
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Loma Linda, California 92354
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
100 N Humphreys Blvd
Memphis, Tennessee 38120
(901) 683-0055
The West Clinic, PC Hello and welcome to our office. Although it is our pleasure...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Midland, Texas 79701
?
mi
from
Midland, TX
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Mission Hills, California 91345
?
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Ocala, Florida 34474
?
mi
from
Ocala, FL
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Paducah, Kentucky 42001
?
mi
from
Paducah, KY
Click here to add this to my saved trials
Phoenix, Arizona 85016
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Quincy, Illinois 62301
?
mi
from
Quincy, IL
Click here to add this to my saved trials
Redondo Beach, California 90277
?
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
?
mi
from
Salem, VA
Click here to add this to my saved trials
Santa Maria, California 93454
?
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Stamford, Connecticut 06902
?
mi
from
Stamford, CT
Click here to add this to my saved trials
?
mi
from
Stockton, CA
Click here to add this to my saved trials
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials